Fosfomycin not noninferior to comparators for bacteremic UTI

(HealthDay)—For patients with bacteremic urinary tract infections (bUTIs) due to multidrug-resistant (MDR) Escherichia coli, fosfomycin is not noninferior to comparators, with an increased rate of adverse event-related discontinuations, according to a study published online Jan. 13 in JAMA Network Open.

This article was originally published on

Read More: